From Evidence to Action: The Rise of Medical-Led Commercialization in Life Sciences

life sciences, everyone pursues the same imperative: getting breakthrough therapies to the people who need them — faster, safer, and with proof they work for specific patient groups.

Despite billions invested in discovery, commercialization hasn’t kept pace. Precision medicine makes up over 80% of new drug approvals, yet the systems meant to bring those therapies to physicians still rely on 1990s logic — mass promotion, data lags from manual analyses, and guesswork disguised as analytics.

With a new $42.5 million Series B round led by NewSpring Capital, joined by Leawood Venture Capital, Blu Ventures and First Trust Capital Partners, Sorcero is scaling what our customers already know: the future of commercialization will be driven by superior medical intelligence.

AI isn’t just drafting text or tagging data. It’s rebuilding the bridge between science and practice.

The adoption gap that impacts lives

Eleven years. That’s how long it takes, on average, for a new therapy to reach routine use.

Doctors aren’t to blame. They’re drowning in complexity. More than 200,000 oncology papers are published each year. New drugs arrive with complex combinations, genetic tests, and evolving safety profiles no human can track alone.

So much is at stake. The impact is personal. My own family member, who was in treatment for breast cancer, her doctor — one of the best in the country — couldn’t keep up with the new genetic targeted therapies. They hadn’t realized a novel test for a specific genetic mutation could unlock eligibility for a life-extending therapy, and the testing sequence for safe administration. All data that had been published in journals, case reports, trial data releases, but hadn’t been compiled together.

A simple genomic test unlocked a new treatment pathway, lifting the prognosis from $13\%$ to $91\%$ survival (PFS). The science was there; the evidence existed. It just hadn’t reached the point of care, even for the best experts—the Key Opinion Leaders (KOLs).

That lag is the difference between innovation and impact. It’s why precision medicine keeps advancing much faster than the healthcare industry can translate it into better patient care.

Commercial intelligence is radically changing

Pharma spends roughly $180 billion a year on marketing and sales, much of it chasing the wrong physicians. Three-quarters of prescriptions are off-label, in key areas like breast cancer, and two-thirds of drug launches still miss their revenue targets. The industry continues to invest in larger data sets and run the same US-based claims-based models that still can’t find the patients who actually qualify for new therapies.

They need a new system of intelligence that turns evidence into action, and does it with regulatory-grade auditability. That’s the shift we call insight-driven commercialization — applying evidence-based medicine to arm medical, safety, access, and commercial teams and it’s already redefining how science reaches physicians.

The question is, how do you turn evidence into action at scale?

Sorcero unifies scientific, medical, and real-world data into a single source of truth — and applies medically tuned, agentic AI to keep that knowledge current, compliant, and personalized.

Across Medical Affairs, Safety, Scientific Communications, and Market Access, Sorcero now powers intelligence systems for more than one-third of the top 30 global pharma companies. Those teams generate insights 18x faster, publish evidence months sooner, and achieve 96 percent clinical inclusion accuracy, surpassing FDA standards and human-expert benchmarks, to make every decision better.

• Unified Intelligence. Connects structured and unstructured data — from clinical studies to real-world evidence — into a continuously validated intelligence.
  
  
• Agentic AI. Every output links to its source, with audit trails that meet GxP, GVP, GDPR, and SOC 2 standards.
  
  
• Global by Design. Built for worldwide deployment, because precision medicine is a global responsibility, not a U.S. use case.

It’s how medical teams move from reporting what happened to proving what works.

Now, services are becoming software

For decades, pharma outsourced evidence generation and analytics to layers of consultants and manual reviewers. That model doesn’t scale. AI is turning those services into software: auditable, repeatable, radically faster, and measurable.

When an MSL can pull a validated answer from a traceable source instead of emailing multiple vendors, teams save months and accelerate patient access to care.

The same transformation is reshaping scientific publishing, safety reporting, and market access. What once took a year and a committee now happens in six weeks with the same rigor and greater transparency. That’s what we mean by AI-native services.

DIY AI is ending

Compliance, reliability, and liability are too high a bar for internal experiments. The next wave of growth will come from domain-specific platforms that deliver trust and measurement by design.

This funding accelerates exactly that. We’re expanding evaluation frameworks, bias testing, and global reach so life-sciences leaders can deploy AI responsibly and prove its impact in weeks, not years.

A new build paradigm is redefining the industry. “It’s no longer build your own AI. It’s build with AI you can trust.”

Companies grow with Sorcero, adding new therapeutic areas, functions, and markets on a platform that learns from your data and governs your risk.

Our partners — Google Cloud, ServiceNow, Snowflake, Springer Nature, and USDM Life Sciences — extend that trust into every workflow where medical judgment and compliance meet AI. Together, we’re building the infrastructure for evidence-based engagement across life sciences worldwide.

The future of science-driven engagement

This isn’t about replacing people with algorithms. It’s about freeing the scientists, medical experts, and communicators who carry precision medicine forward to do what only they can, which is to translate discovery into care.

The Medical Affairs community has been preparing for this moment for years. The unsung heroes of evidence-based medicine, they’ve long bridged the gap between clinical data and clinical practice and now AI is finally giving them the tools to lead.

The next decade of healthcare will be defined by how fast science becomes the standard of care. It’s about shortening the distance from discovery to the first patient dose, aligning regulators, payers, and providers on the same evidence, and rebuilding trust in how AI supports human judgment.

This Series B is a step toward that future, one where every decision is grounded in evidence and every patient benefits sooner. The time for evidence-based action is now—patients can’t wait.